Asgari Maryam M, Chren Mary-Margaret, Warton E Margaret, Friedman Gary D, White Emily
Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA.
Arch Dermatol. 2010 Apr;146(4):388-95. doi: 10.1001/archdermatol.2009.374. Epub 2010 Feb 15.
To examine the association between nonsteroidal anti-inflammatory drug (NSAID) use and cutaneous squamous cell carcinoma (SCC).
Retrospective case-control study.
Kaiser Permanente Northern California (KPNC), a large population based-health maintenance organization.
Random sample of 415 KPNC members diagnosed as having a pathologically verified SCC in 2004 and 415 age-, sex-, and race-matched controls with no history of skin cancer.
Self-reported NSAID use in the 10 years prior to baseline. Use of NSAIDs was categorized based on type (any NSAIDs, aspirin, ibuprofen, and nonaspirin NSAIDs). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression to estimate the association of SCC with regular use, dose, and duration of exposure to the different NSAID types. Information on pharmacy-dispensed NSAIDs was also examined to assess its association with SCC risk. Models were adjusted for all ascertained SCC risk factors (fully adjusted model) and only those variables associated with both SCC risk and NSAID use (parsimonious model).
Fully adjusted analyses showed no statistically significant reduction in SCC risk with self-reported regular use of any NSAID (OR, 1.32; 95% CI, 0.92-1.89), aspirin (OR, 1.38; 95% CI, 0.96-1.97), ibuprofen (OR, 0.74; 95% CI, 0.46-1.19), or nonaspirin NSAIDs (OR, 0.84; 95% CI, 0.56-1.26). Analyses examining duration, dose, and variables combining duration and dose of NSAID exposure did not appreciably change results. An analysis using the parsimonious model showed similar results. The data on pharmacy-dispensed NSAIDs also showed no association with SCC risk.
Neither self-reported nor pharmacy-dispensed NSAID exposure was associated with cutaneous SCC risk.
研究非甾体抗炎药（NSAID）的使用与皮肤鳞状细胞癌（SCC）之间的关联。
回顾性病例对照研究。
北加利福尼亚永久医疗集团（KPNC），一个大型的基于人群的健康维护组织。
随机抽取415名2004年被诊断为经病理证实患有SCC的KPNC成员，以及415名年龄、性别和种族匹配且无皮肤癌病史的对照者。
基线前10年自我报告的NSAID使用情况。NSAID的使用根据类型（任何NSAID、阿司匹林、布洛芬和非阿司匹林NSAID）进行分类。使用条件逻辑回归计算比值比（OR）和95%置信区间（CI），以估计SCC与不同类型NSAID的常规使用、剂量和暴露持续时间之间的关联。还研究了药房配药的NSAID信息，以评估其与SCC风险的关联。模型针对所有已确定的SCC风险因素进行了调整（完全调整模型），以及仅针对那些与SCC风险和NSAID使用均相关的变量进行了调整（简约模型）。
完全调整分析显示，自我报告常规使用任何NSAID（OR，1.32；95%CI，0.92 - 1.89）、阿司匹林（OR，1.38；95%CI，0.96 - 1.97）、布洛芬（OR，0.74；95%CI，0.46 - 1.19）或非阿司匹林NSAID（OR，0.84；95%CI，0.56 - 1.26）时，SCC风险没有统计学上的显著降低。对NSAID暴露的持续时间、剂量以及结合持续时间和剂量的变量进行的分析，结果没有明显变化。使用简约模型的分析显示了类似的结果。药房配药的NSAID数据也显示与SCC风险无关。
自我报告的NSAID暴露和药房配药的NSAID暴露均与皮肤SCC风险无关。
